ÖZET
Amaç:
Çalışmamızın amacı meme kanseri ile ilişkili lenfödem (MKİL) ve sağlıklı popülasyondaki hastalarda plazma D vitamini düzeylerini karşılaştırmak ayrıca sosyo-demografik ve klinik faktörlerin ve lenfödem şiddetinin D vitamini düzeylerine etkilerini tespit etmekti.
Gereç ve Yöntem:
MKİL’li 80 hasta [yaş ortalaması 55,5±8,9 (36-81)] ve kalsiyum ya da Vitamin D tedavisi altında olmayan 80 yaş ve cinsiyet uyumlu sağlıklı kontrol [yaş ortalaması 53,7±7,4 (32-70)] çalışmaya alındı. Olguların sosyo-demografik ve klinik özellikleri sorgulandı. Plazma 25-Hydroxyvitamin D3, kalsiyum, fosfor, alkalen fosfataz (ALP), parathormon (PTH) düzeyleri değerlendirildi. Lenfödem evre 0, I, II veya III olarak sınıflandırıldı.
Bulgular:
Ortalama lenfödem süresi 23,5±13,8 aydı. MKİL’li hastalarda sağlıklı kontrollere oranla daha düşük D vitamini düzeyleri ve daha yüksek PTH ve ALP düzeyleri saptandı. Çok değişkenli regresyon analizi sonucunda, MKİL hastalarında D vitamini düzeyleri ile yaş, meme kanseri evresi ve hastalık süresi arasında anlamlı bir ilişki olduğu ortaya çıkarıldı. Evre 3 lenfödem hastalarında, evre 1’e kıyasla D vitamini düzeyi daha düşük ve PTH düzeyi anlamlı olarak daha yüksekti.
Sonuç:
D vitamini düzeyleri lenfödemli hastalarda sağlıklı kontrollere oranla daha düşük saptanmıştır. Şiddetli lenfödemi olan hastalarda D vitamini düzeylerinin daha düşük saptanmasına rağmen, çok değişkenli regresyon analizi lenfödem şiddetinin D vitamini düzeyleri üzerinde anlamlı bir etkisi olmadığını ortaya koymuştur.
References
1
Laird E, Ward M, McSorley E, Strain JJ, Wallace J. Vitamin D and bone health: potential mechanisms. Nutrients 2010;2:693-724.
2
Peterlik M, Boonen S, Cross HS, Lamberg-Allardt C. Vitamin D and calcium insufficiency-related chronic diseases: an emerging world-wide public health problem. Int J Environ Res Public Health 2009;6:2585-607.
3
Holick MF. Environmental factors that influence the cutaneous production of vitamin D1-3. Am J Clin Nutr 1995;61:638-45.
4
Zhang R, Naughton DP. Vitamin D in health and disease: Current perspectives. Nutr J 2010;9:65.
5
Isenring EA, Teleni L, Woodman RJ, Kimlin MG, Walpole E, Karapetis CS, et al. Serum vitamin D decreases during chemotherapy: an Australian prospective cohort study. Asia Pac J Clin Nutr 2018;27:962-7.
6
Wacker M, Holick MF. Vitamin D effects on skeletal and extraskeletal health and the need for supplementation. Nutrients 2013;5:111-48.
7
de La Puente-Yague M, Cuadrado-Cenzual MA, Ciudad-Cabanas MJ, Hernandez-Cabria M, Collado-Yurrita L. Vitamin D: And its role in breast cancer. Kaohsiung J Med Sci 2018;34:423-7.
8
Davis DD, Milner JA. Nutri genomics, vitamin D and cancer prevention. J Nutrigenet Nutrigenomics 2011;4:1-11.
9
Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN et al. Vitamin D insufficiency and prognosis in non-Hodgkin’s lymphoma. J Clin Oncol 2010;28:4191-8.
10
Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009;27:3757-63.
11
Ren C, Qiu MZ, Wang DS, Luo HY, Zhang DS, Wang ZQ, et al. Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer. J Transl Med 2012;10:16.
12
Wang D, Ve´lez de la Paz OI, Zhai JX, Liu DW. Serum 25- hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. Tumor Biol 2013;34:3509e17.
13
Vaughan-Shaw P, O’Sullivan F, Farrington S, Theodoratou E, Campbell H, Dunlop M, et al. The impact of vitamin D pathway genetic variation and circulating 25- hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. Br J Cancer 2017;116:1092.
14
Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342e57.
15
Wulaningsih W, Sagoo HK, Hamza M, Melvin J, Holmberg L, Garmo H, et al. Serum calcium and the risk of breast cancer: findings from the Swedish AMORIS study and a meta-analysis of prospective studies. Int J Mol Sci 2016;17:1487.
16
Pineda-Moncusi M, Garcia-Perez MA, Rial A, Casamayor G, Cos ML, Servitja S, et al. Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women. Maturitas 2018;116:83-8.
17
American Cancer Society (ACS). Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc., 2013.
18
Fu MR. Breast cancer-related lymphedema: Symptoms, diagnosis, risk reduction, and management. World J Clin Oncol 2014;5:241-7.
19
Chachaj A1, Małyszczak K, Pyszel K, Lukas J, Tarkowski R, Pudelko M, et al. Physical and psychological impairments of women with upper limb lymphedema following breast cancer treatment. Psychooncology 2010;19:299-305.
20
Vassard D, Olsen MH, Zinckernagel L, Vibe-Petersen J, Dalton SO, Johansen C, et al. Psychological consequences of lymphoedema associated with breast cancer: A prospective cohort study. Eur J Cancer 2010;46:3211-8.
21
Dell DD, Doll C. Caring for a patient with lymphedema. Nursing 2006;36:49-51.
22
Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
23
International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. 2009 Consensus document of the International Society of Lymphology. Lymphology 2009;42:51-60.
24
Shao T, Klein P, Grossbarda M. Vitamin D and breast cancer. Oncologist 2012;17:36e45.
25
Welsh J. Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Endocrinol 2011;347:55e60.
26
Shirazi L, Almquist M, Borgquist S, Malm J, Manjer J. Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: a nested case-control study. Breast 2016;28:184e90.
27
Abbas S, Chang-Claude J, Linseisen J. Plasma 25- hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer 2009;124:250e5.
28
Jacot W, Pouderoux S, Thezenas S, Chapelle A, Bleuse JP, Romieu G, et al. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 2012;134:709-17.
29
Shin WK, Kim Z, Youn HJ, Cho J, Lee JE. Determinants of Plasma 25-Hydroxyvitamin D Concentrations among Breast Cancer Survivors in Korea. Nutrients 2018;10.
30
Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and White Americans. N Engl J Med 2013;369:1991-2000.
31
Smoot B, Wong J, Cooper B, Wanek L, Topp K, Byl N, et al. Upper extremity impairments in women with or without lymphedema following breast cancer treatment. J Cancer Surviv 2010;4:167-78.
32
Sezgin Ozcan D, Dalyan M, Unsal Delialioglu S, Duzlu U, Polat CS, Koseoglu BF. Complex Decongestive Therapy Enhances Upper Limb Functions in Patients with Breast Cancer-Related Lymphedema. Lymphat Res Biol 2018;16:446-52.
33
Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg 1999;177:184-7.
34
Chachaj A, Malyszczak K, Pyszel K, Lukas J, Tarkowski R, Pudelko M, et al. Physical and psychological impairments of women with upper limb lymphedema following breast cancer treatment. Psychooncology 2010;19:299-305.
35
Cemal Y, Pusic A, Mehrara BJ. Preventative measures for lymphedema: separating fact from fiction. J Am Coll Surg 2011;213:543-51.
36
Hsieh E, Wang Q, Zhang R, Niu X, Xia W, Fraenkel L, et al. Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps. BMC Cancer 2018;18:104.
37
Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003;56:1038-45.
